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a  b  s  t  r  a  c  t
Despite  condoms  being  cheap  and  effective  in  preventing  HIV,  there  remains  an  8  billion  shortfall  in
condom  use  in risky  sex-acts.  Social  marketing  organisations  apply  private  sector  marketing  approaches
to  sell  public  health  products.  This  paper  investigates  the  impact  of  marketing  tools,  including  promo-
tion  and  pricing,  on demand  for male  and  female  condoms  in 52  countries  between  1997 and  2009.  A
static  model  differentiates  drivers  of demand  between  products,  while  a dynamic  panel  data  estima-
tor  estimates  their  short-  and  long-run  impacts.  Products  are not  equally  affected:  female  condoms  are
not affected  by  advertising,  but  highly  affected  by  interpersonal  communication  and  HIV  prevalence.
Price  and  promotion  have  signiﬁcant  short-  and long-run  effects,  with  female  condoms  far  more  sensi-
tive  to price  than  male  condoms.  The  design  of optimal  distribution  strategies  for  new  and  existing  HIV
prevention  technologies  must  consider  both  product  and  target  population  characteristics.
© 2016  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Since the onset of the HIV epidemic around 50 million HIV infec-
tions have been averted by the use of condoms (Stover, 2014).
Condoms are cheap and highly cost-effective. However, in 2012,
2.3 million people still became infected with HIV (Joint United
Nations Programme on HIV/AIDS, 2013). A recent UNAIDS meeting
identiﬁed a condom gap of over 8 billion condoms, i.e. the difference
between the UNAIDS target condom use in risky sex acts and actual
use, with an annual use of just eight condoms per sexually active
person in sub-Saharan Africa (Deperthes, 2014). Though there is
new optimism that bio-medical tools exist to stem the HIV epi-
demic in the form of anti-retroviral (ARV)-based HIV prevention
(Fauci and Folkers, 2012), these are service intensive, expensive,
and not widely available. Achieving high levels of uptake of pre-
ventive interventions is particularly challenging because it requires
a change in behaviour among populations who may  not perceive
themselves to be at risk, feel ill or face barriers, real or perceived, to
∗ Corresponding author. Tel.: +442079272271.
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accessing products and product support. For condoms and new HIV
prevention products to fulﬁl their public health potential they must
be used widely and effectively; this requires both ensuring consis-
tent and accessible condom supplies and demand creation activities
such as mass media advertising and inter-personal communication
(IEC) promotion approaches.
Though public sector distribution may  be free or very cheap
for consumers to access public health products, it has a number
of potential drawbacks such as limited opening hours, inconsis-
tent supply, and low perceived quality of products and services
(Hanson et al., 2001). Where private sector markets do exist, prices
are often too high for those who need the products most. Addition-
ally, competitive prices will be above the socially optimal price for
HIV prevention because they are not capturing external beneﬁts
to society attributable to reductions in HIV. To ﬁll this gap, social
marketing organisations have been active for decades, initially dis-
tributing subsidised contraceptives including condoms, and more
recently expanding to a range of public health commodities and
services, such as mosquito nets, voluntary counselling and testing
services, and male and female condoms for HIV prevention.
Social marketing is the application of private sector demand cre-
ation tools to stimulate positive behaviour change (Kikumbih et al.,
2005). In particular, consideration is given to the four Ps: product,
http://dx.doi.org/10.1016/j.jhealeco.2016.04.001
0167-6296/© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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promotion, price and place (Grier and Bryant, 2005). Branded
products aim to segment the market and appeal to different user
groups. Promotion applies both generic advertising to increase the
overall market size as well as branded advertising to appeal to
different user groups, and interpersonal communication strategies.
Differentially priced products allow for cross-subsidisation of high
to low priced products, with the higher priced products capturing
more of the consumer surplus, whilst providing a low-end product
to ensure broad access. Additionally, having a sufﬁciently low,
but positive, price aims to instil a sense of value and has been
shown to have lower wastage associated with freely distributed
condoms (Chapman et al., 2012). Subsidised products tend to be
placed within the private sector retail distribution networks to
increase outlets, while being sold by retailers for a proﬁt, to ensure
consistent supply and sustainability. In many countries, social mar-
keting is now the dominant source of condom supply (Chapman
et al., 2012). Because social marketing applies traditional demand
stimulation tools to public health, while public sector distribution
generally does not, it provides an opportunity for studying the
effectiveness of these tools for stimulating demand for new and
existing HIV prevention products, in the absence of private mar-
kets. Understanding drivers of demand for the male and female
condom not only informs programmes on how to better stimulate
demand for existing products, it also provides lessons that can
potentially be applied to the introduction of both new single ARV
based HIV prevention products and multi-purpose products that
prevent both HIV and other infections or unwanted pregnancies.
No recent studies have addressed these questions. Brent (2009)
estimated individual conditional demand for social marketing con-
doms in Tanzania and found a price elasticity around 1 with a strong
inﬂuence of quality on willingness to pay, but did not allow price
elasticity to vary by gender, though 86% of respondents (condom
purchasers) were men. Sweat et al. (2012) reviewed the litera-
ture on the contribution of condom social marketing on condom
use and their meta analysis showed that, though the evidence
is weak, in particular for estimating the cumulative effect over
time, exposure to a condoms social marketing programme doubled
reported condom use among the general population. Differences in
responsiveness between contraceptive products targeting men  and
women have been explored. A few studies provide some guidance
as to the effect of social marketing on male condoms and oral con-
traceptive demand and they showed that the demand for products
responded differently to the same stimulation tools. For exam-
ple, Boone et al. (1985) showed that male condom demand was
much more sensitive to changes in prices and advertising expendi-
tures than oral contraceptive demand. Meekers and Rahaim (2005)
looked at the impact of market environment and showed that,
while male condom demand reacts consistently to variables repre-
senting country level socio-economic context, oral contraceptives
were not signiﬁcantly inﬂuenced by these in most of their anal-
yses. Ciszewski and Harvey (1995) showed that condoms had
much larger and quicker declines in sales than oral contracep-
tives following price increases in Bangladesh. More speciﬁcally
for male and female condoms, a few important product and pro-
gramme  differences suggest potential differences in their demand
responses. Firstly, male condoms have long been distributed and
used as contraceptives, with the additional beneﬁt of reducing
the risk of STI and later HIV. Male condoms have generally been
distributed through a wide range of distribution channels with
minimal training and support for the users. Female condoms were
developed as a method that women could use to protect themselves
from HIV and pregnancy (Warren and Philpott, 2003). However,
female condoms need signiﬁcant introductory support: interper-
sonal communication and peer support groups have been shown
to help women continue to use female condoms (Vijayakumar et al.,
2006).
While these studies have shed some light on how marketing
tools can stimulate demand, they have methodological weaknesses.
None have tested for differences in drivers of demand between
HIV prevention products, nor have any accounted for the fact that
behaviour adjusts slowly to interventions and therefore analyses
that fail to account for this may  obtain biased estimates of the
responsiveness of condom demand to changes in marketing tools
and their long-run effects.
In this paper we explore the drivers of demand for HIV pre-
vention products targeted at women  and men (i.e. female and
male condoms), using unique expenditure and sales data from
Population Services International (PSI), a large international social
marketing organisation, in an unbalanced panel of 52 countries
over 11 years: 1997–2009.1 To the best of our knowledge, this
is the ﬁrst study to conduct an economic/econometric analysis of
the drivers of demand for female and male condoms. In addition
to price, both programmatic demand creation tools (mass media
advertising; ‘information, education, and communication’ (IEC) and
programme effort), as well as the broader country context (income
levels and adult HIV prevalence) are considered as potential drivers
of demand. A dynamic panel data estimator is used to identify the
short- and long-run impact of advertising, price and programme
effort (stafﬁng). This study can guide programmes on how best
to allocate funds across their social marketing tools to maximise
uptake and to inform programming of new HIV prevention prod-
ucts.
Broadly speaking this paper belongs to the advertis-
ing/promotion, and product/service use literature and is hence
close in spirit to some papers in the health economics literature.
Avery et al. (2012) study the impact of direct-to-consumer adver-
tising on antidepressant use in the US, and similarly to this paper,
they make a comparative analysis of female and male use of the
product. Windmeijer et al. (2006) examine the responsiveness of
general practitioners to promotional activities for ethical drugs
by pharmaceutical companies in the Netherlands. Ridley (2015)
investigates price and advertisement elasticities of demand in
the US drug market. Dave and Saffer (2013) show that in the
USA smokeless tobacco advertising both increases the market
demand (primary demand) as well as shifting existing users
to the advertised brand. Moreover they show taxes (i.e. higher
prices) have a differential effect, reducing demand more among
younger male smokers and lower educated individuals. These
papers are all in high income settings and in the context of proﬁt
maximising ﬁrms. Our paper thus complements the economics of
advertising literature by presenting evidence on a very different
type of product, in resource limited settings and for a non-proﬁt
organisation aiming to maximise output.
There is a growing interest in the economics of HIV, with a body
of papers addressing the interaction between HIV and the economy,
or other structural factors such as schooling, gender based vio-
lence, risky sexual behaviour and labour force participation (Alsan
and Cutler, 2013; Baranov et al., 2015; Chin, 2013; Francis, 2008;
Galarraga et al., 2010; Oliva, 2010; Oster, 2012; Wilson, 2012).
Many of these studies raise the challenge of establishing causality
due to endogeneity issues, and address this using an instrumental
variables approach. As another approach to establishing causality,
economists have introduced randomised control trials in particular
to test the impact of incentives on HIV prevention, such as keep-
ing girls in school for longer (Baird et al., 2012), HIV testing (Baird
et al., 2014; Thornton, 2008), staying free from sexually transmitted
infections (de Walque et al., 2012; Galárraga et al., 2014) or volun-
tary medical male circumcision (Thirumurthy et al., 2014). While
1 2005 and 2006 data were not collected centrally and were therefore not available
for  this analysis.
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in general ﬁnancial incentives do induce behaviour change in the
short-run, the impact is not consistent on male and female trial
participants, and the long-run impacts are yet to be assessed. It is
in estimating the long-run impact of marketing tools on behaviour
change (condom use) that this paper contributes to the literature
on the economics of HIV.
The remainder of the paper is organised as follows. Section 2
introduces the conceptual framework for analysing demand, espe-
cially the impact of demand creation tools on sales. Section 3
describes the data and Section 4 outlines the econometric approach.
Section 5 presents and discusses the results and Section 6 con-
cludes.
2. A model of male and female condom demand
The starting point for this analysis is the basic relationships
underlying an aggregate demand model, where the quantity of a
good demanded is a function of its price, the price of its substitutes
(or complements),2 and income. Quantity demanded is proxied by
aggregate country level male and female condom social marketing
sales by PSI. Price is set by country ofﬁces with the aim of high lev-
els of distribution while aiming for sustainability and low wastage
rather than being determined by market forces. Income is proxied
by GDP per capita.
Given our interest in the effect of demand stimulation tools, the
natural starting point is a generic model of the impact of advertise-
ment on sales. The most common dynamic approach to estimating
advertising impact is to specify Koyck’s inﬁnite geometric distribu-
tive lag model (Koyck, 1954), given by
ln(qt) =  ˛ +
∑
j
ˇj ln(Xjt) +  ln(qt−1) + εt,
where qt is condom sales in period t and the X
j
t are variables impact-
ing the quantity of condoms sold.  is a coefﬁcient representing
the habit persistence/speed of adjustment and εt is a random error
term. In this model  lies between 0 and 1. If  is 0, past experience
has no impact on current purchasing decisions; if  is 1, the process
is non-stationary. A larger  implies slower adjustment to external
stimuli.
The short-run marginal effects of the explanatory variables
(advertising and other external stimuli) are represented by ˇ, and
the long-run marginal effect is given by
ˇ
(1 − ) (1)
In the case of advertisement, the expression in (1) is commonly
referred to as ‘carryover’ or ‘goodwill’. To estimate how long it takes
for 90% of the effect to have occurred, we use the 90% duration
interval deﬁned by Clarke (1976) as
(
ln(1 − 0.9)
ln()
)
− 1 (2)
2 Though we would have liked to examine the substitute market in detail, the
substitute markets are not well deﬁned in this case. Conceptually substitutes for
condoms are both contraceptives and HIV prevention products. Alternatively these
could be more narrowly deﬁned as female condoms as substitutes for male condoms
and vice versa. However, the full country level aggregate distribution of each was
not  available for this analysis. An alternative approach would be to deﬁne it more
speciﬁcally as socially marketed products. Prices for social marketing male condoms
were available as the substitute market for female condoms; for male condoms this
approach would result in a very large loss of observations: only 25–50% of condoms
distributing male condoms also distribute female condoms. An alternative deﬁnition
of  the substitute market for male condoms could be to deﬁne a dummy  variable for
the availability of female condoms in the social marketing method mix. Inclusion of
this is explored in the robustness checks presented in Table A6.
As we  are using logarithmic transformations of the variables,
the marginal effects are the short- and long-run elasticities.
In addition, the following determinants of condom demand are
included. Promotion is explored as a composite of mass media
advertising and ‘information, education, and communication’ (IEC)
expenditures as well as in its disaggregated forms. As programmes
can increase the quantities sold in various ways, including expand-
ing distribution systems and improving the consistency of supply,
programme effort (proxied by PSI local salary expenditures) is
included. Acceptability and use of innovations (new products)
increase with exposure (Bass, 1969; Rogers, 1962), we therefore
include a measure of exposure called product maturity, i.e. the num-
ber of years each product has been sold. Although condoms can be
used as a contraceptive, they are also an HIV prevention technology
and their use is thus likely to be related to HIV-risk, represented by
adult HIV prevalence.  In contrast to a typical demand function, the
dependent variable is not individual condom demand, but rather
aggregate country level demand, making the size of the market,
i.e. population size, important. As an issue of special interest, we
will examine whether the relationship under discussion differs by
product type: female versus male condoms.
3. Data
The data consist of country level PSI ﬁnancial accounts used
for routine programme monitoring, supplemented by the World
Bank’s World Development Indicators (WDI)  (World Bank, 2006).
Though PSI distributes a wide variety of public health products,
this analysis focuses exclusively on male and female condom dis-
tribution. We have a total of 385 and 133 observations on male
and female condoms, respectively. The sample includes countries
in Africa, Latin America, Asia and Eastern Europe. The sample used
in the static estimation contains 382 data points for male condoms
and 133 for female condoms. The dynamic estimator requires at
least three years of data to obtain one observation, because of the
need for lags. The dynamic estimation thus had 280 male condom
observations and 85 female condom observations.
Aggregate condom demand is proxied by country level sales of
social marketing male and female condoms in an unbalanced panel
of 633 countries over the period 1997–2009. The deﬁnition and
descriptive statistics of each variable are presented in Table 1. Mean
male condom sales are 100 times larger than mean female condom
sales. Within this dataset, total country programme expenses are
captured by expenditure category: local salaries; advertising and
promotion; and information, education and communication (IEC),
and are allocated across the range of public health products being
distributed. As an illustration PSI country programmes that were
distributing male condoms distributed on average four other prod-
ucts (range 0–19 additional products). Male condom programmes
are generally far larger than female condom programmes, with
mean female condom programme expenditures across these cat-
egories (IEC, advertising and local salaries) ranging from 6% to 9%
of male condom programme expenditures. The WDI  dataset con-
tribute population size, HIV prevalence, and per capita income. All
prices are adjusted to 2011 purchasing power parity (PPP) dollars
($).
Appendix 1 provides an overview of the data availability across
countries and years and the descriptive statistics of the full data set,
including the percentage of observations that were dropped in the
static estimation.
Fig. 1 presents the sales quantities of male and female condoms
over time. Generally, an increasing trend can be seen, with more
3 The number of country programmes increased over time.
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Table 1
Summary statistics.
Variable Deﬁnition, source Data source Male condom programme Female condom programme
Mean*
(Min–Max)
Fraction of zero
values
Mean*
(Min–Max)
Fraction of zero
values
Demand Condom quantity sold PSI 16,729,476.84 163,801
(249–197,030,442) (26–4,238,960)
Price  Condom price PSI $0.09 4.5% $0.36 14.3%
($0–$0.65) ($0–$4.14)
Programme effort Local salary expenditure PSI $1,082,587 1% $115,202 9.8%
($0–$17,580,319) ($0–$1,159,756)
Advertising Advertising expenditures
Advertising refers to mass media
promotion strategies
PSI $776,628 3.7% $64,832 28.6%
($0–$7,897,325) ($0–$690,505)
Information & Education
Campaign
IEC expenditures
IEC refers to one-on-one or small
group intra-personal communication
promotion strategies
PSI $491,159 22.0% $297,789 33.8%
($0–$12,362,417) ($0–$441,515)
Promotion IEC expenditures + advertising
expenditures
PSI $1,267,788 1.6% $95,338 19.5%
($0–$15,761,431) ($0–$690,505)
Product maturity Years of condom product sales PSI 8.13 4.43
(0.2–24) (1–13)
HIV  adult prevalence Prevalence of HIV in the adult
population
WDI  5.64% 8.27%
(0.10%–28.70%) (0.10%–28.60%)
GDP  per capita GDP per capita WDI  $3.642 $3.489
($548–$18,032) ($583–$14,023)
Population Size Population size (in millions) WDI  55.82 55.87
(47.73–71.49) (48.55–69.44)
n  382 133
* Values are presented in natural units (not logarithms).
All  prices are presented in 2011 purchasing power parity dollars.
PSI: Population Services International programme accounts, the social marketing organisation. WDI: World Development Indicators database.
widespread and larger scale male – than female – condom sales.
Condoms sold by region over time can be found in Fig. A1. Africa has
the highest distribution of all condoms, with a substantial number
of male condoms distributed in Asia, while few female condoms
are distributed outside of Africa.
4. Estimation strategy
4.1. Static analysis to compare drivers of demand between
products
We  start with a static model of the demand for male and female
condoms to test for differences between their responsiveness to
the various demand determinants. We estimate static pooled OLS
and ﬁxed effects models where we  include intercept and slope
dummies to distinguish between female and male condoms as fol-
lows:
ln(qkit) =  ˛ + FC +
∑
j
ˇj ln(Xj
kit
) +
∑
j
jFC ∗ ln(Xj
kit
)
+ i + ωt + εkit, k = 1, 2; i = 1, . . .,  N; t = 1, . . .,  T
where k, i and t index respectively: product type (female or male
condoms), country and time period, and FC is a dummy variable
taking the value one if the product is female condom and zero oth-
erwise. As already enumerated in Section 2, the full set of variables
 -
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Fig. 1. Condom sales by product and year (in millions).
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to be explored is: Price of condoms, Promotion (or Advertising and
IEC) and Programme effort, Income, HIV prevalence, Product matu-
rity, and Population size. The i and ωt are country and time effects,
respectively. The country ﬁxed effects absorb the effects of any
unobserved country characteristics, such as geography and cul-
ture. The time ﬁxed effects capture the impacts of factors such as
yearly ﬂuctuations in funding ﬂows that may  affect all country pro-
grammes and both product types in a certain time period. Given
the strain on degrees of freedom, we will also estimate an alterna-
tive speciﬁcation of the time ﬁxed effect by including just a trend
variable.
4.2. Dynamic models of demand
Following our discussion in Section 2, a dynamic model of
demand for each product (female or male condom) can be speciﬁed
as follows:
ln(qi,t) =  ˛ +
∑
j
ˇj ln(Xj
i,t
) +  ln(qi,t−1) + i + ωt + εi,t,
i = 1. . .N; t = 1. . .T
where variables and coefﬁcients are deﬁned as above. As is well
known, the OLS and ﬁxed effects estimators for  are expected to be
biased upwards and downwards, respectively, the latter especially
with a short time series dimension T as we have here. Thus the
ﬁxed effects estimator is likely to imply a higher rate of annual
advertising depreciation (thus a smaller ) compared to estimation
using pooled OLS (Blundell et al., 2000).
The generalised methods of moments (GMM)  estimator pro-
vides a consistent estimation framework for dynamic panel
data models (Arellano and Bond, 1991). With GMM,  the model
is ﬁrst-differenced to remove the country effects i. Then
ln(qi,t−2), ln(qi,t−3), . . .,  ln (qi1) can be used as valid instruments
for the lagged sales difference [ln(qi,t−1) − ln(qi,t−2)], which is
endogenous in the ﬁrst-differenced model. The instruments are
valid as E[(εi,t − εi,t−1) {ln(qi,t−2), ln(qi,t−3), ..., ln(qi1)}] =0, under the
assumption that the εi,t are serially uncorrelated.
It has been shown that the Arellano and Bond estimator suf-
fers from ﬁnite sample weak instruments bias when the series are
persistent (Blundell et al., 2000). To mitigate this problem Blun-
dell and Bond proposed the ‘system’ (SYS) GMM  estimator, which
estimates the parameters based on a combination of levels and dif-
ferences. Speciﬁcally, the SYS-GMM employs the lagged differences
as instruments for the equations in levels, assuming that initial
conditions, like mean-stationarity, are in place such that
E[(vi + εi,t) ln(qi,t−1)] = 0.
The main disadvantage of the GMM  estimation approach is the
loss of degrees of freedom. This loss of degrees of freedom is not ran-
dom: the early years of a sample, which often represent new market
entry, are lost. The GMM  estimator quantiﬁes advertising effects
only in the more mature markets because it includes only groups
with three or more years of sales history. It can thus not provide
information on the relative value of advertising in early years of a
product’s history. Moreover the number of potential instruments
becomes large when there are many time periods and variables;
it is therefore recommended to limit the number of instruments
included. The one-step system GMM  estimator using sequential
instruments dated t − 2 to t − 3 is used to estimate the parame-
ters of the dynamic panel data model (4), using Stata command
xtabond2 (Roodman, 2009).
As the marketing tool variables include zero values, i.e. when
condoms are distributed freely or there were no expenditures for
promotion or local staff, we assign a small value (0.1) to these obser-
vations before taking logs, and include binary indicator variables for
those observations.4 The GMM  estimates are then used to estimate
the long-run effects of the demand stimulation tools on sales, Eq.
(1). The variances of these long-run effects are estimated using the
delta method; in STATA this is done using the ‘nlcom’ post esti-
mation command. We use these to evaluate the signiﬁcance of the
long-run elasticities.
As we mentioned above, prices, promotion and programme
effort are determined by country ofﬁces. After controlling for coun-
try and time ﬁxed effects, the endogeneity of these variables with
respect to demand shocks is limited as normal market forces are
not at work here. There may  of course be some slow responses
to demand shocks, but we  assume that they are such that εi,t and
εi,t−1 do not affect current and one-period lagged prices, promotion
and programme efforts. Under this assumption, the GMM  estima-
tor, only controlling for the endogeneity of lagged demand, will
consistently estimate the short- and long-run effects.
Our dynamic panel data framework allows us to treat all vari-
ables as endogenous, but at a cost of weaker identiﬁcation and an
increasing number of instruments. As a robustness check, we also
estimate the dynamic model parameters by GMM,  treating prices,
promotion and programme effort as endogenous, using lagged lev-
els dated t − 2 and t − 3 as instruments for the ﬁrst-differences and
lagged changes dated t − 1 as instruments for the levels.
5. Empirical results
5.1. Main results
As already discussed our aim is to understand the drivers of
demand and whether they vary by product, in order to inform
the appropriate approach to demand stimulation (i.e. which type
of marketing tool will give the greatest increase in sales per dol-
lar spent). Table 2 presents the results of the static pooled OLS
and ﬁxed effects models with female condom dummy  variables
to test for differences in the determinants of demand. The pooled
OLS model is rejected in favour of the FE model allowing for esti-
mated country ﬁxed effects; we  therefore focus on the FE estimates.
The Log-likelihood Ratio (LR) test could not reject the year trend in
favour of the 10 year-speciﬁc effects; as such time is captured by a
trend in the presented models. The results with alternative speciﬁ-
cations of the time effects are presented in Appendix Table A5. The
results are very similar, though the IEC*female condom interaction
variable loses signiﬁcance in the alternative speciﬁcation.
Country effects and coefﬁcients for the ‘Year’ trend and ‘No
expenditures’ dummies (No advertising, No local salaries, No IEC,
free products, respectively) are not presented. Table A6 presents
the same model run separately for Male and Female condoms,
but including HIV prevention substitutes in the marketing mix
(female condoms as substitutes for male condom, and the price
of substitutes (the price of male condoms as a driver of demand for
female condoms).
The signs of the marketing coefﬁcients conform to expecta-
tions: Advertising, IEC and Programme Effort all have positive signs
while Price has a negative sign. In the ﬁxed effects model Price
and Programme Effort are not signiﬁcant at conventional levels of
signiﬁcance.5 Price does however have a signiﬁcant negative effect
(elasticity −0.453, p < 0.00) on condom sales when estimated jointly
for both products (not shown).
The static ﬁxed effects model suggests considerable differences
between male and female condom demand responses, with female
4 The magnitude of the ‘small value’ does not affect the estimates in any way.
5 To explore the possibility that price is driven by country ﬁxed effects, we have
run a regression of price on country- and year-speciﬁc ﬁxed effects. The coefﬁcient
of  determination is very low (r-squared = 0.31) suggesting otherwise.
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Table 2
Estimation results: static model of the demand for condoms.
Dependent variable:
Ln country condom sales
(1) (2)
Pooled OLS Fixed effects
Variables Year as trend Year as trend
Constant 21.330 (30.68) −84.41 (62.11)
Female condom dummy  (FC) 2.423 (2.215) 0.385 (1.996)
Ln  advertising 0.241*** (0.085) 0.192*** (0.067)
*FC −0.199* (0.116) −0.192* (0.101)
Ln  IEC 0.124*** (0.044) 0.081** (0.032)
*FC 0.162 (0.121) 0.176* (0.105)
Ln  own  price −0.230*** (0.076) −0.123 (0.100)
*FC −0.246* (0.143) −0.179 (0.133)
Ln  programme effort 0.231*** (0.075) 0.131 (0.081)
*FC −0.148 (0.194) −0.035 (0.178)
Ln  GDP per capita 0.108 (0.096) −0.530 (0.407)
*FC 0.002 (0.198) 0.146 (0.188)
Ln  population size 0.407*** (0.050) −0.036 (1.293)
*FC −0.242** (0.114) −0.317*** (0.122)
Ln  adult HIV prevalence 0.055* (0.033) 0.445* (0.259)
*FC 0.282** (0.112) 0.336*** (0.097)
Ln  product maturity 0.484*** (0.075) 0.383** (0.150)
*FC 0.004 (0.193) −0.048 (0.243)
Year  −0.011 (0.015) 0.050 (0.039)
Observations 515 515
R-squared 0.865 0.930
LR-test  (H0: no country effects) 335***
Robust standard errors (clustered by country) in parentheses.
* p < 0.1.
** p < 0.05.
*** p < 0.01.
condoms being more responsive than male condoms to: IEC, Pop-
ulation size and HIV prevalence and less (to the point of not at all)
responsive to mass media advertising.
This static approach is arguably satisfactory for exploring dif-
ferences in the determinants of demand by product. However,
as discussed in the previous section, demand is expected to be
driven not only by current marketing strategies, but also by pre-
vious period investments. In such cases a dynamic model is more
appropriate. A one-step system GMM  estimator is used to esti-
mate the short- and long-run effects of promotion, prices and
programme effort and country contexts and the duration of their
effects (Table 3). ‘Promotion’ is here deﬁned as the sum of mass
media advertising and IEC as estimation of separate effects led to
unstable results.
The speciﬁcation tests for the GMM  estimator are satisﬁed, i.e.
we ﬁnd 1st order serial correlation (ar1), albeit slightly above con-
ventional p-values, and no 2nd order serial correlation (ar2). The
Hansen test does not reject the over-identifying conditions. The
large Hansen p-value for the female condom estimates is caused
by the small sample size. Conforming to expectations, the system
GMM  estimate for  lies between the OLS and FE estimates.
Qualitatively, the three estimators provide reasonably consis-
tent results, particularly for male condoms and for the presence of
persistence and effectiveness of promotion for increasing demand.
In contrast to the signiﬁcantly positive coefﬁcient on population
size in the GMM  model, the OLS and ﬁxed effects models did not
identify this effect.
Both the male and female condom display signiﬁcant persis-
tence, with male condom demand slower to adjust to stimuli than
female condom demand, as seen in the relatively higher  in the
male condom estimates (0.570) relative to the female condom esti-
mates (0.347). It takes 3.1 and 1.2 years for 90% of the cumulative
effects to be exhausted, respectively, for male and female condoms.
Short- and long-run male condom demand is driven largely by
promotion, price and population size. The GMM  estimates show
that the short-run impact of a 10% increase in promotion spend-
ing is 1.66%, whereas such an investment is expected to increase
demand by 3.85% in the long-run. A 10% increase in price is
expected to generate a 0.82% decrease in male condom demand
in the short-run, increasing to 1.92% in the long-run. Programme
effort has no immediate or long-run effect. It can be further seen
that income, as proxied by GDP per capita, and product matu-
rity or HIV prevalence do not signiﬁcantly affect male condom
demand.
In the female condom ﬁxed effects model all coefﬁcients lose
signiﬁcance except product age and promotion which is likely
attributable to the small sample size. Demand for female con-
doms changes more rapidly than demand for the male condom
( = 0.347). The short-run effect of a 10% increase in promotion
spending is 1.78% rising to 2.72% in the long-run. Price has a very
large effect on demand, with a 10% price increase leading to a
3.60% and a 5.51% decrease in demand in the short- and long-run,
respectively. In contrast to male condom demand, female condom
demand is affected by HIV prevalence in both the short- and long-
run.
5.2. Robustness checks
As robustness checks, for the demand for male condoms we
have estimated these relationships under a variety of alternative
GMM speciﬁcations. One speciﬁcation excludes Eastern European
which and Central Asian countries from the estimation sample.
Another treats prices, promotion and programme efforts as endoge-
nous, as described above. These speciﬁcations do not qualitatively
change the results (see Table A8). Estimation of the ‘ordinary’ ﬁrst-
differenced GMM  did result in considerably different results (see
Table A8). The model with instrumented prices, promotion and
programme effort shows a higher rate of persistence ( = 0.714),
and higher short-run and long-run promotion and price elastici-
ties (short-run 0.208 and −0.111, long-run: 0.727 and −0.387). As
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Table  3
Estimation results: dynamic panel data model of the demand for condoms.
Dependent variable:
Ln country condom sales
Dynamic male condom estimates Dynamic female condom estimates
Variables OLS Fixed effects GMM  OLS Fixed effects GMM
Lag Ln condom sales 0.755*** 0.540*** 0.570*** 0.451*** 0.186 0.347***
(0.0792) (0.123) (0.113) (0.114) (0.188) (0.124)
Ln  promotion 0.160*** 0.139*** 0.166*** 0.166* 0.165* 0.178**
(0.0514) (0.0518) (0.0612) (0.0875) (0.0889) (0.0874)
Ln  price −0.0524 −0.172*** −0.0826* −0.335** −0.171 −0.360***
(0.0538) (0.0608) (0.0490) (0.120) (0.108) (0.110)
Ln  programme effort 0.0501 0.142 0.112 −0.0605 −0.122 −0.0513
(0.0700) (0.115) (0.0885) (0.102) (0.126) (0.0798)
Ln  GDP per capita −0.00652 0.207 −0.00341 −0.0123 −0.818 0.00253
(0.0712) (0.383) (0.0773) (0.170) (3.057) (0.188)
Ln  product age −0.0456 −0.117 0.0872 0.178 2.754* 0.344
(0.0683) (0.199) (0.113) (0.303) (1.348) (0.333)
Ln  population size 0.0569 1.554 0.148** 0.177 −12.50 0.185
(0.0618) (0.972) (0.0645) (0.124) (17.03) (0.116)
LN  adult HIV prevalence 0.00799 0.532*** 0.0189 0.173 0.188 0.215*
(0.0237) (0.192) (0.0262) (0.122) (0.793) (0.117)
ar1p  0.137 0.130
ar2p  0.521 0.390
hansenp 0.165 0.973
Long  term effects
Promotion 0.385** (0.161) 0.272** (0.145)
Price −0.192** (0.097) −0.551*** (0.152)
Programme effort 0.261 (0.177) −0.079 (0.127)
GDP  per capita −0.008 (0.180) 0.004 (0.29)
Product age 0.203 (0.227) 0.527 (0.446)
Population size 0.345*** (0.100) 0.283* (0.170)
Adult HIV prevalence 0.044 (0.062) 0.329** (0.154)
Observations 280 85
R-squared 0.889 0.570 0.761 0.616
Number of countries 58 26
Robust standard errors in parentheses.
Parameters for the constant, year, country and dummy’s for no promotion, free condoms and no stafﬁng are not shown, but available upon request.
* p < 0.1.
** p < 0.05.
*** p < 0.01.
discussed, this speciﬁcation has weaker identiﬁcation due to the
instrumentation of all the variables, which also leads to quite a
large number of instruments, relative to the sample size, may  bias
the estimates.
For the original speciﬁcation, the results did not change when
adding qi,t−4 as a further instrument for the differences (not shown).
Because Zimbabwe had far higher female condom sales than
the other countries and contributed 10% of the observations, we
removed its observations to check for its inﬂuence on the results;
again the results remain broadly intact when excluding Zimbabwe
(not shown).
5.3. Study limitations
Within the scope of HIV prevention products, the full substi-
tute market was not observed. We only analysed data on condom
sales through PSI; the free public sector was not incorporated
nor was the private condom sector (in the few countries where
it existed). When considering condoms as contraceptives, there
exist both private and public markets for contraceptives in these
countries, which were also not captured. We did however run our
static models capturing the price of PSI male condoms as the price
of substitute for female condoms and found no signiﬁcant effect,
while programmes selling female condoms had signiﬁcantly higher
male condom sales (Table A6). The study period covered the intro-
duction of HIV treatment in some countries. Though the general
trend is captured by the time dummies, ideally it would have been
included in more detail. Other variables that theoretically should
have been included were: Gini coefﬁcient (to account for aggrega-
tion bias in country level analyses), and age and sex distribution of
the population (to capture the at-risk population). Complete time
series data on these variables across our sample countries were
not available and changed little over the study period, however the
country and time effects remove biases potentially introduced by
their omission.
Though this dataset is the largest of its kind that can be used
to estimate the effects of marketing tools on condom sales, it is
relatively small compared to many other analyses of advertising
and price elasticities of demand.
The social marketing data may  contain measurement error and
inconsistencies over time and countries attributable to the follow-
ing factors. While PSI has provided ﬁnancial data on the allocation of
costs from 1997 to 2009, it should be noted that during this time-
frame, PSI implemented a rolling upgrade of its ﬁnancial system,
which contributes to some variation in the data by country and year.
Reporting requirements by PSI funders sometimes vary, leading to
differences in allocations of costs between expenditure categories.
Allocations of shared expenditures across products may  not have
been applied consistently. The data do not differentiate between
generic and branded promotional expenditures. The measurement
error could lead to attenuation bias, which can then be part of the
reason why  we  ﬁnd bigger effects when treating all variables as
endogenous.
Despite these limitations, we  ﬁnd largely robust results, in par-
ticular for the male condom analysis. The female condom results
should be considered indicative rather than conclusive due to the
smaller sample size. These results are largely consistent with the lit-
erature of advertising impact, however given the products at hand
and the country settings, direct comparison of the magnitude of
demand elasticities is not productive.
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6. Conclusions
This study aimed to evaluate the effectiveness of social market-
ing tools in stimulating demand for male and female condoms. It
contributes to the literature by comparing their effects on prod-
ucts targeting men  (male condoms) and products sold mainly to
women (female condoms) and by estimating both short- and long-
run effects (allowing for condom use behaviour to adjust slowly)
using a dynamic model that also controls for potential endogeneity.
We have shown that marketing tools do not have a consistent
impact across condom types, in line with the contraception liter-
ature on oral contraceptive versus condoms (reviewed in Section
1). Mass media advertising is an important marketing tool for male
condoms. Advertising is however not found to be effective in stim-
ulating demand for female condoms. IEC appears important for all
condoms with a slightly stronger impact on female than male con-
doms. For both products, promotion and price have strong long-run
effects, approximately doubling the short-run effects.
More research needs to be done to better understand the differ-
ences between the price elasticities of demand between the male
and female condom; in particular to disentangle price and income
effects: i.e. are the effects truly attributable to differences in price
levels and products, or are they more related to the user groups,
with female condoms targeted particularly for purchase by women,
known to have lower ability to pay. Care needs to be taken when
setting prices to ensure they remain consistent with social mar-
keting aims: i.e. sufﬁciently low to not form a barrier to demand,
while reducing wastage, instilling a sense of value associated with
the products and reducing stigma (Brent, 2009, 2010).
The ﬁndings of this paper have a number of policy implica-
tions. Firstly, despite the fact that condoms remain one of the most
cost-effective approaches to preventing HIV (Schwartländer et al.,
2011), the global HIV prevention community is increasingly look-
ing towards new HIV prevention products (Stover et al., 2014). This
study shows that with consorted effort including promotion and
low product pricing, demand for condoms can be increased, with
lasting effects, and should not be forgotten as part of a combination
prevention approach to the HIV epidemic.
Secondly, our results provide guidance for developing demand
creation approaches for these new HIV prevention products: it
is important to consider the target user as well as the product
characteristics. If sold, consideration to purchasing power of
the intended target users may  be critical to the scale of their
distribution, as well as the fact that the product price is only part
of the cost of product use; many people face high costs to access
health services, both in terms of direct transport costs and labour
time lost. Social marketing can play a critical role in diversifying
distribution outlets to bring products to more accessible locations
and in increasing demand and reduce product stigma through
interpersonal communication and mass media advertising, while
complementing public sector free distribution to ensure access to
public health products for those with less ﬁnancial resources.
Finally, analyses of the impact of behaviour change interven-
tions need to consider that many changes in human behaviours,
in particular preventive ongoing behaviours, are slow to adjust.
Where appropriate data exist, estimating dynamic models, as done
in this analysis, should reduce the bias otherwise present and
improve the interpretation of coefﬁcients for policy applications.
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Fig. A1. Condom sales by region (in millions).
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Table  A1
Summary statistics of full sample.
Variable Deﬁnition, source Male condom programme Female condom programme
N Mean* % of values dropped
in estimation
N *Mean % of values dropped
in estimation
(Min–Max) (Min–Max)
Demand Condom quantity
sold, PSI
430 15,900,000 10% 155 147,802 14%
(249–197,000,000) (26–4,238,960)
Price  Condom price, PSI 416 $0.10 7% 142 $0.37 6%
($0–$0.95) ($0–$4.14)
Programme effort Local salary
expenditures, PSI
416 $1,065,602 7% 145 $116,555 8%
($0–$17,600,000) ($0–$1,159,756)
Advertising Advertising
expenditures, PSI
416 $778,457 7% 145 $64,170 8%
Advertising refers
to mass media
promotion
strategies,
($0–$8,263,314) ($0–$690,505)
Information & Education
Campaign (IEC)
IEC expenditures,
PSI
416 $467,164 7% 145 $28,930 8%
IEC  refers to
one-on-one or
small group
intra-personal
communication
promotion
strategies
($0–$12,400,000) ($0–$441,515)
Promotion IEC expendi-
tures + advertising
expenditures, PSI
416 $1,240,311 7% 144 $93,746 8%
($0–$15,800,000) ($0–$690,505)
Product maturity Years of condom
product sales, PSI
430 8.89 10% 155 4.21 14%
(0.2–24) (1–13)
HIV  adult prevalence Prevalence of HIV
in  the adult
population, WDI
394 5.53% 2% 141 8.16% 6%
(0.10–28.70%) (0.10–28.70%)
GDP  per capita GDP per capita,
WDI
406 $4.150 5% 139 $3.576 4%
($548–$22,630) ($583–$14,023)
Population Size Population size (in
millions), WDI
406 66,700,000 5% 139 80,600,000 4%
(293,544–1,330,000,000) (301,016–1,330,000,000)
* Values are presented in natural units (not logarithms).
All  prices are presented in 2011 purchasing power parity dollars.
PSI: Population Services International programme accounts, the social marketing organisation. WDI: World Development Indicators database.
Sample used in the static estimation contains 382 observations for male condoms and 133 for female condoms. The dynamic estimator requires at least 3 years of data to
obtain  1 observation, because of the need for lags. The dynamic estimation thus had 280 male condom observations and 85 female condom observations.
Table A2
Overview of panel data structure (number of country’s programmes distributing
each condom type by year).
Year Male condom Female condom
1997 11 3
1998 21 4
1999 37 7
2000 36 9
2001 43 11
2002 43 15
2003 48 16
2004 44 19
2007 44 17
2008 51 26
2009 52 28
Total 430 155
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Table A3
Male condom data availability.
Country Year
1997 1998 1999 2000 2001 2002 2003 2004 2007 2008 2009
Afghanistan 1 1
Albania 1 1 1 1 1
Angola 1 1 1 1 1 1 1
Belize  1 1
Benin  1 1 1 1 1 1 1 1 1 1 1
Bolivia 1 1 1 1 1
Botswana 1 1 1 1 1 1 1 1 1
Burkina Faso 1 1 1 1 1 1 1
Burundi 1 1 1 1 1 1 1 1 1
Cambodia 1 1 1 1 1 1 1 1
Cameroon 1 1 1 1 1 1 1 1 1 1
Caribbean 1
Central African Republic 1 1 1 1 1 1 1 1
Central America 1 1 1 1 1 1 1 1
Chad  1 1 1
China 1 1 1 1
Congo (Dem. Rep. & Rep.) 1 1 1
Congo,  Dem. Rep. 1 1 1 1
Congo, Rep. 1 1 1 1
Costa  Rica 1 1
Cote  d’Ivoire 1 1 1 1 1 1 1 1 1 1 1
Cuba  1 1
Dominican Republic 1 1 1 1 1
El  Salvador 1 1
Eritrea 1 1 1 1 1 1
Ethiopia 1 1
Georgia 1 1 1 1
Guatemala 1 1
Guinea 1 1 1 1 1 1 1 1 1 1 1
Guinea-Bissau 1 1 1
Guyana 1
Haiti  1 1 1 1 1 1 1 1 1 1 1
Honduras 1 1
India  1 1 1 1 1 1 1 1 1 1 1
Kazakhstan 1 1 1 1 1
Kenya 1 1 1 1 1 1 1 1 1 1
Kosovo 1 1 1
Kyrgyzstan 1 1 1 1 1
Lao  PDR 1 1 1 1 1 1 1 1 1
Lesotho 1 1 1 1 1 1
Lesotho & Swaziland 1 1 1
Liberia 1
Madagascar 1 1 1 1 1 1 1 1 1
Malawi 1 1 1 1 1 1 1 1 1 1
Mali  1 1 1 1 1 1 1
Mexico 1 1 1
Mozambique 1 1 1 1 1 1 1 1 1 1
Myanmar 1 1 1 1 1 1 1 1 1
Namibia 1 1 1 1 1 1 1 1 1 1
Nepal  1 1
Nicaragua 1 1
Nigeria 1 1 1 1 1 1 1 1 1 1
Pakistan 1 1 1 1 1 1 1 1 1
Panama 1
Papua  New Guinea 1 1 1
Paraguay 1 1 1 1 1 1 1 1 1
Romania 1 1 1 1 1 1 1 1 1 1
Russian Federation 1 1 1 1 1 1 1 1 1 1
Rwanda 1 1 1 1 1 1 1 1 1 1
South  Africa 1 1 1 1 1 1 1 1 1 1
Sudan 1 1
Swaziland 1 1 1 1
Tajikistan 1 1 1 1
Tanzania 1 1 1 1 1 1 1 1 1
Thailand 1 1 1 1 1
Togo  1 1 1 1 1 1 1 1 1 1 1
Uganda 1 1 1 1 1 1 1 1 1
Uzbekistan 1
Vietnam 1 1 1
Zambia 1 1 1 1 1 1 1 1 1 1
Zimbabwe 1 1 1 1 1 1 1 1 1 1 1
Total  11 21 37 36 43 43 48 44 44 51 52
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Table  A4
Female condom data availability.
Country Year
1997 1998 1999 2000 2001 2002 2003 2004 2007 2008 2009
Belize 1
Benin 1 1
Bolivia 1 1 1 1 1
Botswana 1 1 1 1
Burkina Faso 1
Cambodia 1 1 1
Cameroon 1 1 1 1 1 1
Caribbean 1
Central African Rep. 1 1
Central America 1 1 1 1 1 1
China  1 1 1 1
Congo (Dem. Rep. & Rep.) 1
Congo,  Dem. Rep. 1 1
Congo, Rep. 1
Costa  Rica 1
Cote  d’Ivoire 1
El  Salvador 1 1
Guatemala 1 1
Guinea-Bissau 1 1
Haiti 1 1 1 1 1 1 1 1 1 1 1
India  1 1 1
Lesotho 1 1 1 1
Lesotho & Swaziland 1 1 1
Madagascar 1 1
Malawi 1 1
Mali  1 1 1 1 1 1
Mozambique 1 1 1 1 1 1 1 1
Myanmar 1 1 1 1 1
Namibia 1 1
Nicaragua 1 1
Nigeria 1
Papua New Guinea 1 1
Paraguay 1 1 1 0 0
South  Africa 1 1 1 1 1 1 1 1 1 1
Swaziland 1
Tanzania 1 1 1 1 1 1 1 1 1
Togo  1 1 1 1 1 1 1 1 1
Uganda 1
Vietnam 1 1 1
Zambia 1 1 1 1 1 1 1 1 1 1
Zimbabwe 1 1 1 1 1 1 1 1 1 1 1
Total  3 4 7 9 11 15 16 19 17 26 28
Table A5
Correlation matrix.
Ln
condom
sales
Ln
promotion
Ln
advertising
Ln
IEC
Ln
price
Ln
programme
effort
Ln
product
age
Substitute
(dummy)
Ln GDP
per
capita
Ln
population
size
Ln adult HIV
prevalence
Male condom (N = 382)
Ln male condom sales 1.00
Ln  promotion 0.30 1.00
Ln  advertising 0.32 0.70 1.00
Ln  IEC 0.16 0.26 0.09 1.00
Ln  price 0.13 0.09 0.24 −0.04 1.00
Ln programme effort 0.28 0.83 0.57 0.23 0.10 1.00
Ln  product age 0.53 0.02 0.07 0.22 0.05 0.06 1.00
Substitute (dummy) 0.21 0.08 0.06 0.22 0.01 0.05 0.16 1.00
Ln  GDP per capita −0.19 −0.07 −0.13 −0.02 −0.06 −0.06 −0.22 −0.01 1.00
Ln  population size 0.56 0.17 0.08 0.06 −0.11 0.14 0.24 −0.00 0.00 1.00
Ln  adult HIV prevalence 0.17 0.01 0.08 −0.04 −0.05 0.01 0.32 0.29 −0.24 −0.20 1.00
Female condom (N = 131)
Ln female condom sales 1.00
Ln  promotion 0.22 1.00
Ln  advertising 0.33 0.80 1.00
Ln  IEC 0.20 0.70 0.48 1.00
Ln  price 0.33 0.15 0.30 −0.02 1.00
Ln programme effort 0.19 0.45 0.34 0.39 0.06 1.00
Ln  product age 0.50 −0.08 0.07 0.14 0.21 −0.06 1.00
Substitute (dummy) −0.09 −0.03 0.10 −0.11 0.52 0.04 0.03 1.00
Ln  GDP per capita −0.18 −0.17 −0.11 −0.22 −0.36 −0.13 −0.12 −0.11 1.00
Ln  population size 0.16 0.01 0.03 −0.09 0.09 −0.10 0.05 0.02 −0.03 1.00
Ln  adult HIV prevalence 0.46 −0.06 −0.01 −0.05 0.23 −0.02 0.41 −0.17 −0.07 −0.14 1.00
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Table A6
Estimation results (robustness check): static model with year-speciﬁc effects.
Variables (1) (2) (3) (4)
OLS trend FE trend i.c OLS i.y FE i.y i.c
Constant 21.33 −84.41 −0.816 18.03
(30.68) (62.11) (1.354) (19.35)
Female condom dummy  2.423 0.385 2.543 0.349
(2.215) (1.996) (2.205) (1.975)
Ln  Advertising 0.241*** 0.192*** 0.245*** 0.192***
(0.0846) (0.0665) (0.0858) (0.0665)
*FC −0.199* −0.192* −0.211* −0.196*
(0.116) (0.101) (0.116) (0.1000)
Ln  IEC 0.124*** 0.0812** 0.136*** 0.0893***
(0.0444) (0.0315) (0.0451) (0.0334)
*FC 0.162 0.176* 0.136 0.148
(0.121) (0.105) (0.125) (0.107)
Ln  Own  Price −0.230*** −0.123 −0.242*** −0.129
(0.0763) (0.100) (0.0789) (0.0987)
*FC −0.246* −0.179 −0.274* −0.201
(0.143) (0.133) (0.146) (0.134)
Ln  Programme Effort 0.231*** 0.131 0.211*** 0.120
(0.0752) (0.0813) (0.0765) (0.0826)
*FC −0.148 −0.0349 −0.144 −0.0424
(0.194) (0.178) (0.190) (0.176)
Ln  GDP per capita 0.108 −0.530 0.126 −0.555
(0.0963) (0.407) (0.0991) (0.416)
*FC 0.00248 0.146 −0.00630 0.149
(0.198) (0.188) (0.199) (0.186)
Ln  Population Size 0.407*** −0.0364 0.409*** −0.207
(0.0501) (1.293) (0.0499) (1.332)
*FC −0.242** −0.317*** −0.230** −0.298**
(0.114) (0.122) (0.113) (0.121)
Ln  Adult HIV prevalence 0.0547* 0.445* 0.0525 0.503*
(0.0327) (0.259) (0.0331) (0.284)
*FC 0.282** 0.336*** 0.281** 0.333***
(0.112) (0.0972) (0.114) (0.0980)
Ln  product maturity 0.484*** 0.383** 0.493*** 0.372**
(0.0752) (0.150) (0.0739) (0.149)
*FC 0.00396 −0.0477 0.0131 −0.0269
(0.193) (0.243) (0.193) (0.246)
Year  −0.0112 0.0496
(0.0153) (0.0390)
Observations 515 515 515 515
R-squared 0.865 0.930 0.868 0.931
LR-test 2 versus 1 3 versus 1 4 versus 2
335*** 12.2 12.8
Robust standard errors in parentheses.
* p < 0.1.
** p < 0.05.
*** p < 0.01.
Table A7
Estimation results: static model including substitutes/substitute price.
Dependent variable Ln quantity Male condom, FE Female condom, FE
Ln advertising 0.194*** (−0.069) −0.0486 (−0.121)
Ln  IEC 0.087*** (−0.029) 0.299** (−0.127)
Ln  own  price −0.143 (−0.099) 0.0959 (−0.165)
Substitute dummy; Ln Psubstitute for FC model 0.328*** (−0.103) −1.733 (−2.698)
Ln  programme effort 0.096 (−0.081) 0.0832 (−0.123)
Ln  GDP per capita −0.119 (−0.357) −4.247* (−2.151)
Ln  population size −0.788 (−1.134) 12.81 (−8.678)
Ln  adult HIV prevalence 0.665*** (−0.229) 1.513* (−0.843)
Ln  product maturity 0.523*** (−0.121) 0.541 (−0.489)
Year  0.0129 (0.036) −0.090 (0.136)
Constant −2.494 (−56.52) 12.41 (−204.4)
Observations 381 132
R-squared 0.9 0.854
Robust standard errors in parentheses.
* p < 0.1.
** p < 0.05.
*** p < 0.01.
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Table  A8
Robustness checks of the dynamic male condom model under alternative speciﬁcations.
Variables Base: systems GMM  1st-differenced GMM  Lags 2–4 Excl. EurAsia Endogenous price, promotion
and programme effort
Lag Ln condom sales 0.503*** −0.125 0.503*** 0.844*** 0.714***
(0.135) (0.208) (0.135) (0.0957) (−0.0892)
Ln  promotion 0.165** 0.0602 0.162** 0.135* 0.208***
(0.0664) (0.0516) (0.0664) (0.0726) (−0.0764)
Ln  price −0.0845 −0.0383 −0.0857 −0.0510 −0.111*
(0.0525) (0.0934) (0.0522) (0.0475) (−0.0651)
Ln  programme effort 0.128 −0.0187 0.128 −0.00286 0.0185
(0.0881) (0.226) (0.0876) (0.0599) (−0.0989)
Ln  GDP per capita −0.00420 1.114 −0.00406 0.0217 0.0295
(0.0798) (0.957) (0.0798) (0.0626) (−0.076)
Ln  product age 0.102 0.0650 0.103 −0.0984 −0.0168
(0.131) (0.453) (0.131) (0.101) (−0.0879)
Ln  population size 0.191** 1.838 0.192*** 0.0400 0.0665
(0.0746) (2.547) (0.0747) (0.0471) (−0.074)
Ln  adult HIV prevalence 0.0205 0.372 0.0206 0.0217 0.00765
(0.0292) (0.268) (0.0294) (0.0211) (−0.0248)
Iyear 1998 0.0326 0.0317 −0.00573
(0.137) (0.136) (−0.119)
Iyear 1999 0.250 0.0805
(0.183) (0.111)
Iyear 2000 −0.237** 0.255 −0.237** −0.177* −0.275***
(0.106) (0.274) (0.106) (0.0974) (−0.0999)
Iyear 2001 −0.0177 0.489 −0.0169 −0.0180 −0.0116
(0.115) (0.341) (0.115) (0.0793) (−0.105)
Iyear 2002 −0.0805 0.510 −0.0800 0.0309 −0.0856
(0.113) (0.454) (0.113) (0.104) (−0.108)
Iyear 2003 −0.113 0.596 −0.113 −0.0558 −0.12
(0.0967) (0.551) (0.0965) (0.0842) (−0.0885)
Iyear 2004 0.0335 0.660 0.0328 0.0412 0.044
(0.116) (0.650) (0.116) (0.0883) (−0.112)
Iyear 2008 −0.0391 0.257** −0.0402 0.109 0.0452
(0.165) (0.127) (0.167) (0.146) (−0.116)
Iyear 2009 −0.375** −0.375** −0.279** −0.333**
(0.164) (0.164) (0.110) (−0.135)
Constant 0.534 0.537 0.0831 0.0652
(1.108) (1.113) (0.803) (−1.053)
ar1  p-value 0.128 0.786 0.126 0.0175 0.159
ar2  p-value 0.514 0.428 0.517 0.514 0.435
Sargan p-value 0.0937
Hansen p-value 0.201 0.319 0.289 1.00
Observations 280 190 280 267 280
Number of countries 58 46 58 53 58
Long-run effects
Ln Promotion 0.332** 0.054 0.327** 0.332** 0.727*
(0.155) (0.045) (0.154) (0.155) (0.392)
Ln  rice −0.170* −0.034 −0.172* 0.170* −.387
(0.090) (0.086) (0.090) (0.09) (0.231)
Ln  programme effort 0.257* −0.017 0.258* 0.257 0.065
(0.149) (0.199) (0.149) (0.085) (0.334)
Ln  GDP per capita −0.008 0.990 −0.008 −0.008 0.103
(0.161) (0.898) (0.161) (0.161) (0.264)
Ln  product age 0.206 0.058 0.206 0.206 −0.058
(0.220) (0.398) (0.220) (0.22) (0.318)
Ln  population size 0.385*** 1.633 0.387*** 0.385*** 0.232
(0.385) (2.355) (0.089) (0.089) (0.213)
Ln  adult HIV prevalence 0.041 0.330 0.041 0.041 0.027
(0.058) (0.196) (0.058) (0.058) (0.088)
Robust standard errors in parentheses.
* p < 0.1.
** p < 0.05.
*** p < 0.01.
Coefﬁcients for the dummy variables indicating variable imputation for 0 values of price, promotion and stafﬁng are not shown.
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